An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia

Leukemia

Volumn 25, Issue 10, 2011, Pages 1639-1645

  Herold, T ^a   Jurinovic, V ^b   Metzeler, K H ^a   Boulesteix, A L ^b   Bergmann, M ^a,d   Seiler, T ^a   Mulaw, M ^c   Thoene, S ^c   Dufour, A ^a   Pasalic, Z ^a   Schmidberger, M ^b   Schmidt, M ^b   Schneider, S ^a   Kakadia, P M ^a,c   Feuring Buske, M ^d   Braess, J ^a   Spiekermann, K ^a,c   Mansmann, U ^b   Hiddemann, W ^a,c   Buske, C ^d   Bohlander, S K ^a,c   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; MICRORNA;

CANCER GROWTH; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION SIGNATURE; GENE EXPRESSION SYSTEM; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LETTER; MICROARRAY ANALYSIS; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 80054040682     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.125     Document Type: Letter

References (10)

1. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo clinic experience. Blood 2009; 114: 957-964.
2. Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 4473-4479.
3. Zainuddin N, Murray F, Kanduri M, Gunnarsson R, Smedby KE, Enblad G et al. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res 2011; 35: 272-274.
4. Gunnarsson R, Isaksson A, Mansouri M, Goransson H, Jansson M, Cahill N et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia 2010; 24: 211-215.
5. Rodriguez A, Villuendas R, Yanez L, Gomez ME, Diaz R, Pollan M et al. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia 2007; 21: 1984-1991. (Pubitemid 47299974)
6. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801. (Pubitemid 41549891)
7. Kienle D, Benner A, Laufle C, Winkler D, Schneider C, Buhler A et al. Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica 2010; 95: 102-109.
8. Stamatopoulos B, Haibe-Kains B, Equeter C, Meuleman N, Soree A, De Bruyn C et al. Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. Haematologica 2009; 94: 790-799.
9. Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010; 16: 903-908.
10. Flach H, Rosenbaum M, Duchniewicz M, Kim S, Zhang SL, Cahalan MD et al. Mzb1 protein regulates calcium homeostasis, antibody secretion, and integrin activation in innate-like B cells. Immunity 2010; 33: 723-735.